BIBN 99

BIBN 99
Names
IUPAC name
N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • Key: LUPAFPUKESJDMZ-UHFFFAOYSA-N
  • InChI=1S/C31H42ClN5O3/c1-5-15-31(3,4)30(40)36(6-2)17-8-9-22-13-18-35(19-14-22)21-27(38)37-26-12-11-23(32)20-24(26)29(39)34-25-10-7-16-33-28(25)37/h7,10-12,16,20,22H,5-6,8-9,13-15,17-19,21H2,1-4H3,(H,34,39)
  • CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=C(C=C(C=C3)Cl)C(=O)NC4=C2N=CC=C4
Properties
C31H42ClN5O3
Molar mass 568.16 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

BIBN 99 is an antagonist of mACh receptors. Specifically, it is selective for the M2 type, and was prototypical for this class of selective compounds. BIBN 99 is lipophilic, it crosses the blood-brain barrier and is a competitive antagonist of the M2 receptor with 30-fold selectivity over M1 receptors.

Effects

During research, it was observed that BIBN 99 was able to diminish the cognitive deficits caused by injury. Another also came to the conclusion that the compound could provide cognitive improvements. The cognitive effects could possibly be caused by the increased release of acetylcholine, a neurotransmitter.